Natera, Inc. (NASDAQ:NTRA)‘s stock had its “buy” rating reaffirmed by analysts at Canaccord Genuity in a research note issued on Tuesday. They currently have a $15.00 target price on the medical research company’s stock. Canaccord Genuity’s price target points to a potential upside of 60.60% from the company’s previous close.

NTRA has been the topic of a number of other reports. ValuEngine lowered shares of Natera from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Cowen and Company reiterated a “buy” rating and set a $14.00 price target on shares of Natera in a research note on Friday, September 1st. Robert W. Baird reiterated a “buy” rating on shares of Natera in a research note on Tuesday, October 24th. Zacks Investment Research lowered shares of Natera from a “buy” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of Natera in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $15.00.

Shares of Natera (NASDAQ:NTRA) traded up $0.15 on Tuesday, reaching $9.34. 128,900 shares of the company traded hands, compared to its average volume of 199,823. Natera has a 12-month low of $7.35 and a 12-month high of $14.76. The company has a debt-to-equity ratio of 2.43, a quick ratio of 1.75 and a current ratio of 1.85.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $56.66 million during the quarter, compared to analysts’ expectations of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.50) earnings per share. analysts expect that Natera will post -2.12 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Natera, Inc. (NTRA) Earns Buy Rating from Canaccord Genuity” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/11/14/natera-inc-ntra-earns-buy-rating-from-canaccord-genuity.html.

In other news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total transaction of $1,504,800.00. Following the completion of the transaction, the insider now directly owns 533,208 shares of the company’s stock, valued at $6,686,428.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 12.57% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Capital World Investors grew its position in shares of Natera by 0.8% during the second quarter. Capital World Investors now owns 4,222,609 shares of the medical research company’s stock worth $45,858,000 after buying an additional 32,000 shares in the last quarter. Jennison Associates LLC grew its position in shares of Natera by 1.0% during the second quarter. Jennison Associates LLC now owns 2,356,346 shares of the medical research company’s stock worth $25,590,000 after buying an additional 23,473 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Natera by 12.6% during the second quarter. Vanguard Group Inc. now owns 2,261,052 shares of the medical research company’s stock worth $24,555,000 after buying an additional 253,344 shares in the last quarter. Macquarie Group Ltd. grew its position in shares of Natera by 25.9% during the third quarter. Macquarie Group Ltd. now owns 1,336,993 shares of the medical research company’s stock worth $17,234,000 after buying an additional 275,113 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Natera by 1.5% during the second quarter. Bank of New York Mellon Corp now owns 634,743 shares of the medical research company’s stock worth $6,893,000 after buying an additional 9,223 shares in the last quarter. 60.54% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.